Back to search

University of British Columbia

Engineering flavanone biosynthesis in yeast towards the production of montbretin A

Abstract

dc:description

Plants produce a diverse range of specialized metabolites, which are an important source for new pharmaceuticals. The plant metabolite montbretin A (MbA) is a novel therapeutic for type 2 diabetes. MbA is a complex acylated flavonol glycoside found in the underground storage organs, called corms, of the ornamental plant montbretia (Crocosmia x crocosmiiflora). Large quantities of MbA are needed to treat the millions of people who would benefit from it. However, MbA cannot be extracted from montbretia corms in sufficient quantities for therapeutic use, and chemical synthesis of MbA is not viable due to the compound’s chemical complexity. Engineering a plant or microbial system for large-scale, sustainable MbA production would be a viable option. The recent elucidation of the complete MbA biosynthetic pathway provides the tools to engineer yeast (Saccharomyces cerevisiae) for heterologous MbA production. The core of MbA is the flavonol myricetin, the biosynthesis of which needs to be bioengineered in yeast. In most plants, biosynthesis of myricetin uses coumaric acid as a substrate and produces naringenin as a flavanone intermediate. However, utilizing metabolic engineering of myricetin from coumaric acid via naringenin poses a problem for the downstream bioengineering of MbA in yeast. The presence of coumaric acid would lead to formation of MbB instead of MbA, where MbB contains a coumaroyl side chain instead of the caffeoyl side chain in MbA. MbB is an undesired by-product with no known therapeutic value. To address this problem, I developed a yeast strain that uses caffeic acid (instead of coumaric acid) in the formation of myricetin via eriodictyol (instead of naringenin). I achieved the formation of eriodictyol as a precursor to myricetin at 27.3 mg * L⁻¹. Optimizing flavonoid enzyme combinations, tuning gene expression, and the addition of the chalcone isomerase-like (CHIL) protein improved eriodictyol production up to 8-fold. Overall, this work demonstrates the potential of engineering a yeast strain to produce the flavanone eriodictyol, an essential step towards scalable and sustainable production of the anti-diabetic plant metabolite MbA.

Degree

thesis:*
Name thesis:degree_name
Master of Science - MSc
Level thesis:degree_level
master's
Discipline thesis:degree_discipline
Genome Science and Technology
Grantor dc:publisher
University of British Columbia
Year dc:date
2022

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Liu, Le
Contributors dc:contributor
  • Bohlmann, Jörg

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/82389

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Liu, Le. Engineering flavanone biosynthesis in yeast towards the production of montbretin A. master's thesis, University of British Columbia, 2022. http://hdl.handle.net/2429/82389